StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Wednesday. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Down 8.1 %

Shares of NYSE:NBY opened at $0.52 on Wednesday. The firm has a market cap of $3.01 million, a P/E ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $9.08. The business has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.64.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.